

Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Lead Product(s) : Sodium Zirconium Cyclosilicate
Therapeutic Area : Nephrology
Study Phase : Phase IV
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sodium Zirconium Cyclosilicate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hyperkalemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 15, 2024
Lead Product(s) : Sodium Zirconium Cyclosilicate
Therapeutic Area : Nephrology
Highest Development Status : Phase IV
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sodium Zirconium Cyclosilicate
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Update on CRYSTALIZE Evidence Trials
Details : Lokelma (sodium zirconium cyclosilicate) is an anti-hyperkalaemia (HK) therapy that provides rapid potassium reduction and sustained potassium control.15 It is indicated for the treatment of Hyperkalaemia (HK) in adults.
Product Name : Lokelma
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 01, 2023
Lead Product(s) : Sodium Zirconium Cyclosilicate
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sodium Zirconium Cyclosilicate
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lokelma (sodium zirconium cyclosilicate) is an anti-hyperkalaemia (HK) therapy that provides rapid potassium reduction and sustained potassium control.15 It is indicated for the treatment of Hyperkalaemia (HK) in adults.
Product Name : Lokelma
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 02, 2023
Lead Product(s) : Sodium Zirconium Cyclosilicate
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Sodium Zirconium Cyclosilicate
Therapeutic Area : Nephrology
Study Phase : Phase IV
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sodium Zirconium Cyclosilicate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hyperkalemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 10, 2022
Lead Product(s) : Sodium Zirconium Cyclosilicate
Therapeutic Area : Nephrology
Highest Development Status : Phase IV
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sodium Zirconium Cyclosilicate
Therapeutic Area : Nephrology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study
Details : Sodium Zirconium Cyclosilicate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hyperkalemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 26, 2022
Lead Product(s) : Sodium Zirconium Cyclosilicate
Therapeutic Area : Nephrology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sodium Zirconium Cyclosilicate
Therapeutic Area : Nephrology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The designation is based on the potential of LOKELMA to reduce serious adverse CV outcomes in this patient population, addressing a significant unmet medical need.
Product Name : Lokelma
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 17, 2021
Lead Product(s) : Sodium Zirconium Cyclosilicate
Therapeutic Area : Nephrology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sodium Zirconium Cyclosilicate
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sodium Zirconium Cyclosilicate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Renal Insufficiency, Chronic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 24, 2021
Lead Product(s) : Sodium Zirconium Cyclosilicate
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sodium Zirconium Cyclosilicate
Therapeutic Area : Nephrology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of SZC and Enhanced Nutrition Advice Compared to SoC in Dialysis Patients With Hyperkalaemia
Details : Sodium Zirconium Cyclosilicate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hyperkalemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 09, 2021
Lead Product(s) : Sodium Zirconium Cyclosilicate
Therapeutic Area : Nephrology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sodium Zirconium Cyclosilicate
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sodium Zirconium Cyclosilicate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hyperkalemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 19, 2021
Lead Product(s) : Sodium Zirconium Cyclosilicate
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sodium Zirconium Cyclosilicate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Michael Fu
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sodium Zirconium Cyclosilicate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Heart Failure.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 09, 2021
Lead Product(s) : Sodium Zirconium Cyclosilicate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Michael Fu
Deal Size : Inapplicable
Deal Type : Inapplicable
